SUMMARY
OBJECTIVE To determine the epidemiological characteristics of deaths from COVID-19 in Peru from March 28 to May 21, 2020, 85 days after the report of the first confirmed case.
MATERIAL AND METHODS Case series type study. Deaths from various sources were investigated, including the COVID-19 Epidemiological Surveillance and the National System of Deaths. Deaths that met the definition of a confirmed case and had a positive (reactive) result of RT-PCR or rapid test were considered for the analysis. From these sources, epidemiological variables were obtained and a time analysis was performed, defining as the pre-hospital time the time from the onset of symptoms to the date of hospitalization and hospital time from the date of hospitalization to the date of death.
RESULTS 3,244 confirmed deaths were included in the study. Deaths were more frequent in males (71.8%), elders (68.3%), residents of the department of Lima (41.8%), and others from the coast (37.7%). In 81.3% of cases, the death occurred in a public hospital, 16.0% died at home, shelter, penitentiary institution, public highway, or in transit to a hospital, and 31.1% had some comorbidity.
Statistical difference was observed in pre-hospital time according to age group (p <0.001) and gender (p = 0.037), being significantly higher in adults, elders, and women. There was a statistically significant difference in hospital time according to geographic area, showing a significantly shorter time in the departments of the coast (p <0.001) and Andean region (p = 0.014) compared to Lima. The cases that were seen in private clinics (p = 0.001) survived longer than those seen in public hospitals.
CONCLUSION Deaths from COVID-19 occur mainly in male, elders, on the coast, with considerable deaths at home, in shelters, penitentiaries, public roads, or in transit to a hospital. Pre-hospital time is affected by age group and gender; while, hospital time is also influenced by the region of origin and the health care provider.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The authors did not receive financial support for the research, authorship, and/or publication of this article.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The protocol was approved by the IRB of the Research Institute in Biomedical Sciences of the Universidad Ricardo Palma and has the authorization to be published by the CDC Ministry of Health of Peru.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Conflict of interests: The authors have no conflicts of interest to declare. This manuscript is the sole responsibility of the authors and does not represent an official opinion of the Ministerio de Salud del Perú, Centro Nacional de Epidemiología, Prevención y Control de Enfermedades, Universidad Nacional Mayor de San Marcos, Universidad Ricardo Palma y Programa de Especialización en Epidemiología de Campo.
Funding: The authors did not receive financial support for the research, authorship, and/or publication of this article.
Data Availability
The databases consulted and the sources are freely accessible and available.
https://www.dge.gob.pe/portal/docs/tools/coronavirus/coronavirus300420.pdf
https://www.dge.gob.pe/portal/docs/tools/coronavirus/coronavirus200520.pdf.
https://www.dge.gob.pe/portal/docs/tools/coronavirus/coronavirus310320.pdf
https://www.dge.gob.pe/portalnuevo/covid-19/covid-cajas/situacion-del-covid-19-en-el-peru/
